Tirzepatide (TZP) is a dual glucose-dependent insulinotropic (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist approved by the Food and Drug Administration (FDA) for the management of diabetes since May 2022 and obesity since November 2023. The gene discussed is GLP1R; the disease is obesity disorder.